メタ情報
| meta description平均長 | 176.44 |
|---|
| OGPありページ数 | 1 |
|---|
| Twitterカードありページ数 | 0 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 850 |
|---|
| ページあたり内部リンク平均 | 169.8 |
|---|
内部リンク 深さヒストグラム
| キー | 値 |
|---|
| 0 | 55 |
| 1 | 384 |
| 2 | 608 |
| 3 | 1721 |
| 4 | 606 |
| 5 | 2 |
| 7 | 1 |
| 8 | 19 |
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| PDF | 1 |
| BioNTech | 0.626669 |
| COVID | 0.581928 |
| today | 0.294292 |
| Vaccine | 0.282406 |
| announced | 0.282174 |
| vaccine | 0.25967 |
| European | 0.157533 |
| Authorization | 0.144144 |
| FDA | 0.142629 |
| Phase | 0.13964 |
| age | 0.131566 |
| President | 0.128104 |
| Omicron | 0.124641 |
| organisations | 0.121622 |
| mRNA | 0.119448 |
| Vice | 0.119369 |
| COMIRNATY | 0.119369 |
| Food | 0.114865 |
| Administration | 0.114865 |
| Emergency | 0.114865 |
| BNT | 0.11036 |
| patient | 0.106481 |
| years | 0.104224 |
| data | 0.100474 |
| dose | 0.096943 |
| Chief | 0.095562 |
| SARS | 0.095212 |
| Drug | 0.094135 |
| CoV | 0.093481 |
| personal | 0.093481 |
| funding | 0.092342 |
| Use | 0.090751 |
| Executive | 0.087004 |
| older | 0.085586 |
| Years | 0.085586 |
| you | 0.084943 |
| use | 0.079655 |
| Medicines | 0.078829 |
| Candidate | 0.078829 |
| individuals | 0.078446 |
| EMA | 0.076577 |
| Officer | 0.075042 |
| CHMP | 0.074324 |
| Agency | 0.074324 |
| booster | 0.074324 |
| adapted | 0.072072 |
| PAXLOVID | 0.06982 |
| your | 0.069309 |
| Site | 0.067568 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| announced | today | 5.302152 | 604 |
| CoV | SARS | 4.868402 | 216 |
| Drug | Food | 4.717453 | 225 |
| Administration | Drug | 4.704291 | 224 |
| States | United | 4.494123 | 212 |
| President | Vice | 4.469119 | 200 |
| age | years | 4.460619 | 279 |
| Emergency | Use | 4.323315 | 200 |
| Agency | Medicines | 4.320932 | 129 |
| Executive | Officer | 4.272236 | 208 |
| Administration | Food | 4.109928 | 168 |
| Administration | FDA | 4.068445 | 208 |
| discussed | herein | 4.06093 | 80 |
| Inc | today | 4.025051 | 472 |
| ritonavir | tablets | 3.997901 | 95 |
| Executive | Vice | 3.990225 | 160 |
| organisations | patient | 3.989858 | 193 |
| Authorization | Use | 3.977093 | 191 |
| Agency | EMA | 3.953636 | 108 |
| Chief | Officer | 3.934925 | 190 |
| Development | Research | 3.904167 | 108 |
| transfer | value | 3.833137 | 101 |
| Biologics | License | 3.813429 | 60 |
| Sweden | Switzerland | 3.733923 | 59 |
| COVID | Vaccine | 3.722742 | 636 |
| Age | Years | 3.698132 | 88 |
| Authorization | Emergency | 3.683716 | 145 |
| different | labeling | 3.653545 | 60 |
| Chief | Executive | 3.653243 | 160 |
| data | personal | 3.631047 | 187 |
| only | residents | 3.62792 | 80 |
| booster | dose | 3.61261 | 112 |
| nirmatrelvir | tablets | 3.606875 | 76 |
| Policy | Privacy | 3.570247 | 84 |
| Adapted | Bivalent | 3.560086 | 68 |
| intended | only | 3.544111 | 84 |
| PAXLOVID | nirmatrelvir | 3.505385 | 72 |
| charitable | contributions | 3.47475 | 60 |
| Application | License | 3.44683 | 60 |
| party | third | 3.446204 | 77 |
| BioNTech | today | 3.436 | 507 |
| Security | Social | 3.423484 | 37 |
| Executive | President | 3.401896 | 145 |
| Finland | France | 3.389248 | 51 |
| European | Union | 3.384608 | 121 |
| BioNTech | Pfizer | 3.380335 | 1314 |
| Antiviral | Oral | 3.373152 | 48 |
| Czech | Republic | 3.369631 | 36 |
| European | Medicines | 3.351095 | 128 |
| Human | Products | 3.312772 | 67 |
被リンク情報
このデータの閲覧には会員登録が必要になります。会員登録